23andMe (ME) Scheduled to Post Earnings on Wednesday

23andMe (ME) Scheduled to Post Earnings on Wednesday

23andMe (NASDAQ:ME – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, February 7th. Parties that wish to listen to the company’s conference call can do so using this link.

23andMe (NASDAQ:ME – Get Free Report) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.16) earnings per share for the quarter. 23andMe had a negative net margin of 124.34% and a negative return on equity of 47.68%. The company had revenue of $50.00 million for the quarter, compared to analysts’ expectations of $56.80 million.

23andMe Stock Performance
NASDAQ:ME opened at $0.74 on Wednesday. The stock’s fifty day moving average is $0.84 and its 200 day moving average is $1.03. 23andMe has a fifty-two week low of $0.61 and a fifty-two week high of $2.99. The firm has a market capitalization of $356.03 million, a PE ratio of -1.02 and a beta of 1.40.

Insider Buying and Selling

In related news, insider Kathy L. Hibbs sold 38,548 shares of 23andMe stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $0.73, for a total transaction of $28,140.04. Following the completion of the transaction, the insider now directly owns 1,280,349 shares in the company, valued at $934,654.77. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 154,192 shares of company stock valued at $125,281 over the last quarter. 27.55% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On 23andMe

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ME. Vanguard Group Inc. raised its holdings in shares of 23andMe by 25.8% in the 3rd quarter. Vanguard Group Inc. now owns 23,643,554 shares of the company’s stock valued at $67,621,000 after buying an additional 4,842,320 shares during the period. BlackRock Inc. increased its holdings in 23andMe by 4.9% during the 2nd quarter. BlackRock Inc. now owns 19,330,109 shares of the company’s stock worth $33,828,000 after purchasing an additional 910,127 shares during the period. State Street Corp increased its holdings in 23andMe by 10.3% during the 2nd quarter. State Street Corp now owns 6,183,243 shares of the company’s stock worth $10,821,000 after purchasing an additional 576,924 shares during the period. Finally, Geode Capital Management LLC increased its holdings in 23andMe by 4.7% during the 2nd quarter. Geode Capital Management LLC now owns 5,617,120 shares of the company’s stock worth $9,830,000 after purchasing an additional 254,321 shares during the period. Institutional investors and hedge funds own 28.23% of the company’s stock.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.

Share:
error: Content is protected !!